{"title":"大麻二酚（Epidiolex）","authors":"Cadth","doi":"10.51731/cjht.2024.887","DOIUrl":null,"url":null,"abstract":"\nCADTH recommends that Epidiolex be reimbursed by public drug plans as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older, if certain conditions are met. \nEpidiolex should only be covered to treat patients aged 2 years or older who have a clinical diagnosis of seizures associated with LGS and experience at least 2 drop seizures per week over the course of 28 days, and whose seizures are not adequately controlled with 2 or more other antiseizure medications. \nEpidiolex should be reimbursed if prescribed by a physician with expertise in the diagnosis and management of patients with LGS and if the price of Epidiolex is reduced. \n","PeriodicalId":505661,"journal":{"name":"Canadian Journal of Health Technologies","volume":"27 30","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cannabidiol (Epidiolex)\",\"authors\":\"Cadth\",\"doi\":\"10.51731/cjht.2024.887\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\nCADTH recommends that Epidiolex be reimbursed by public drug plans as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older, if certain conditions are met. \\nEpidiolex should only be covered to treat patients aged 2 years or older who have a clinical diagnosis of seizures associated with LGS and experience at least 2 drop seizures per week over the course of 28 days, and whose seizures are not adequately controlled with 2 or more other antiseizure medications. \\nEpidiolex should be reimbursed if prescribed by a physician with expertise in the diagnosis and management of patients with LGS and if the price of Epidiolex is reduced. \\n\",\"PeriodicalId\":505661,\"journal\":{\"name\":\"Canadian Journal of Health Technologies\",\"volume\":\"27 30\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian Journal of Health Technologies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.51731/cjht.2024.887\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Health Technologies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51731/cjht.2024.887","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
CADTH recommends that Epidiolex be reimbursed by public drug plans as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older, if certain conditions are met.
Epidiolex should only be covered to treat patients aged 2 years or older who have a clinical diagnosis of seizures associated with LGS and experience at least 2 drop seizures per week over the course of 28 days, and whose seizures are not adequately controlled with 2 or more other antiseizure medications.
Epidiolex should be reimbursed if prescribed by a physician with expertise in the diagnosis and management of patients with LGS and if the price of Epidiolex is reduced.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
